Arvinas LLC has announced a strategic collaboration with Merck in which Arvinas’ novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics. The multi-year collaboration will encompass multiple disease targets across several therapeutic areas.
“We look forward to working with Merck to create novel drugs to address difficult targets,” said Manuel Litchman, M.D., President and CEO of Arvinas.
While the specifics of the financial arrangements were not disclosed, Arvinas will receive an up-front payment and funding to support Merck-related research. Additionally, Arvinas could earn up to $434 million if all research, development, regulatory and commercial milestone payments are successfully paid for products against all the targets initially selected by Merck, as well as tiered royalties.